Anzeige
❌
Mehr »
Samstag, 28.02.2026 - Börsentäglich über 12.000 News
Wegweisende News: NurExone - Pionier der regenerativen neuronalen Medizin!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: 157088 | ISIN: BG11SOSOBT18 | Ticker-Symbol: 3JR
Frankfurt
27.02.26 | 21:43
1,770 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
OSTEUROPA
1-Jahres-Chart
SOPHARMA AD Chart 1 Jahr
5-Tage-Chart
SOPHARMA AD 5-Tage-Chart

Aktuelle News zur SOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSopharma AD: Consolidated quarterly financial report1x3news
FrSopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
DoSopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20145x3news
SOPHARMA Aktie jetzt für 0€ handeln
MiSopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
DiSopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
MoSopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
20.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
16.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20144x3news
13.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
12.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
11.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
11.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
10.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
09.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
06.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
05.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20144x3news
04.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20143x3news
03.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20142x3news
02.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
02.02.Sopharma AD: Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/20141x3news
1 2 3 4 Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1